RADX
Radiopharm TheranosticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Composite grade F from latest DB weights. Momentum 12.2 / Value 46.4
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
12
Value
46
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $14.63
Why
Momentum12 · Δ7d -
Value46 · Δ7d +0.0
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
12
40% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
46
60% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.0
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 12.2 / Value 46.4
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$50.81M
Beta
-
Shares Out
11.81M
P/E (TTM) · Derived
-1.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.84
Rev YoY
-
EPS YoY
-
Gross Margin
-56.9%
Op Margin
-
Net Debt
-$19.08M
Current Ratio
3.01
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology